

Review

Not peer-reviewed version

Neurotrophic Viruses in the Pathogenesis of ALS

[Jay Lombard](#)^{*} and [Andres D. Klein](#)^{*}

Posted Date: 2 June 2023

doi: 10.20944/preprints202306.0139.v1

Keywords: ALS; TDP-43; misfolded proteins; enterovirus; polio; motor neurons; retrotransposons; prions; Alzheimer's



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Review

Neurotrophic Viruses in the Pathogenesis of ALS

Jay Lombard ^{1,*} and Andres D. Klein ^{2,*}

¹ Private practice, New City, NY, USA

² Centro de Genética y Genómica, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, Santiago 7780272, Chile

* Correspondence: contact@drjaylombard.com (J.L.); andresklein@udd.cl (A.D.K.)

Abstract: Treatment of neurological disease is hampered by the lack of validated specific and sensitive biomarkers, resulting in delayed diagnosis and nonspecific disease modifying therapies. For example, in ALS the lack of a sensitive and specific biomarker impedes the ability to administer a treatment prior to or at the onset of motor neuron dysfunction. Although viral or other infectious etiologies have been proposed as a contributing factor to neurodegeneration, it can be argued that these are casual and not causal associations. In the case of ALS, evidence for direct causality would require *in vivo* validation of specific nucleotide sequences of microbial origin which are known to be neuroinvasive with tropism for motor neurons, such as polio and non-polio. Several viral enteropathogens recapitulate the pathological events in sporadic ALS, including the ability to cleave TDP-43 resulting in accumulation of misfolded proteins in the cytoplasm. This review provides supporting evidence that motor neuron disease is causally related to specific enteroviruses and argues that prospective validation is imperative for effective prevention and treatment.

Keywords: ALS; TDP-43; misfolded proteins; enterovirus; polio; motor neurons; retrotransposons; prions; Alzheimer's

Introduction

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by the loss of upper and lower motor neurons in the motor cortex, brain stem and the anterior horn of the spinal cord. The etiology ALS is currently unknown, however the incidence in the number of cases across the world is projected to increase by almost 70% in the next two decades [1], suggesting a confluence of genetic and sporadic factors. Among several sporadic factors, a viral etiology has previously been proposed based upon the similarities between the molecular phenotype of ALS and enteroviruses [2].

Several related enteropathogens including polio, Coxsackie and other enteroviruses such as EV-71 have been associated with motor neuron dysfunction, but these are normally acute bases which do not progress in a step wise progression as does ALS. Further, the findings of viral genetic material in the CSF of ALS patients as previously reported can be argued as being incidental and not causal [3]. Causality based biomarkers in ALS require the fulfillment of the revised Koch criterion where a specific nucleic acid sequence corresponding to a putative pathogen is present in most cases of affected patients, but not present in unaffected patients [4]. An additional criterion to fulfill the revised Koch postulate is whether the pathological mechanisms of a particular infection are consistent with protein misfolding of RNA binding proteins which are characteristic hallmarks of ALS. In the following paragraphs we will argue that enteroviruses exert alternative splicing of host RNA resulting in post translational modifications of proteins which recapitulate the hallmark features of neurodegeneration including the accumulation of intrinsically disordered proteins which self-aggregate and cross seed unaffected cells in a prion like manner.

TDP-43 hyperphosphorylation in ALS

Among genes linked to ALS, mutations in the gene encoding for Transactive response DNA binding Protein of 43 kDa (*TDP-43*) have been linked to familial and sporadic cases [5]. The involvement of TDP-43 in neurodegeneration was first reported when hyperphosphorylated TDP-43 was observed in the majority of patients with ALS and frontal lobar degeneration [6]. As an RNA binding protein, TDP-43 binds to more than 6,000 mRNA targets, representing nearly 30% of the entire transcriptome [7–9].

TDP-43 hyperphosphorylation leads to protein aggregation and misfolded RNA binding proteins as the hallmark of ALS and other neurodegenerative diseases, such as Niemann-Pick type C (NPC) [10,11].

As early as 1995, it was noted that TDP-43 acts as a transcriptional repressor of HIV-1 infection by inhibiting viral assembly [12]. More recently, TDP-43 has been shown to affect viral fusion and infection capacities in an epigenetic manner by altering HDAC6 levels and tubulin-deacetylase levels involved in a microtubule function [13]. Subsequent studies confirmed that hyperphosphorylated TDP-43 impairs small interfering RNA silencing, which is the major post-transcriptional mechanism of retrotransposable elements or genomic parasites as a novel mechanism of neurodegeneration in ALS [14]. TDP-43 has been shown to contain a prion-like domain that can form a self-replicating amyloid conformation [15] TDP-43 possesses intrinsically disordered domains whereby the rate α -helix-to- β -sheet transition is dependent upon post translational modifications of phosphorylation-dephosphorylation pathways [16]. Furthermore, prion-like domains may directly originate during viral genomic RNA processing involving nucleocapsid (NC) proteins responsible for virus capsid assembly and structure [17]. To date, approximately 70 human RNA-binding proteins have been reported to possess a prion-like domain and render intracellular proteins more prone to misfolding and aggregation [18].

For example, prion-like RNA binding domains have also been recognized in fused sarcoma (*FUS*), the most aggressive, early-onset forms of ALS [19]. Mutations in *FUS* are also associated with misfolded RNA bindings proteins in an identical matter as TDP-43 [20]. In a similar manner, *FUS* mutations are more sensitive to retroviruses and exacerbate cytoplasmic mislocalization and protein misfolding [21]

The misfolding of proteins in ALS gives rise to hydrophobic PrP^{Sc} aggregates which are insoluble filaments comprised of amyloid and tau like plaque. Prior studies have demonstrated that β -amyloid aggregates exhibit many properties indistinguishable from those of prions, including the ability of amyloid fibrils to self-propagate [22].

These observations suggest that common mutations in ALS disinherit host mediated viral repression by targeting prion like domains, resulting in protein aggregation and motor neuron degeneration in a prion like manner.

Part I: Enteroviruses in the etiology of motor neuron disease

Enteroviruses are now regarded as the most important neurotropic enterovirus in the Asia-Pacific region in the post-polio eradication era [22,23].

Collectively, Enteroviruses are single-stranded positive-sense neurotrophic RNA viruses including polio, coxsackievirus A and B types, and numerous other enteroviruses, including EV-68 and EV-71 [24]. EVs are non-enveloped viruses comprised of a viral capsid that contains a single open reading frame (ORF) which encodes four structural proteins, VP1–4 and seven non-structural proteins (2A–C and 3A–D) including RNA-dependent RNA polymerase (3D^{Pol}) [25].

Enteroviruses are primarily transmitted through the fecal–oral route where infections can be limited to febrile illnesses but in more severe cases can result in meningitis, brainstem encephalitis, and acute flaccid myelitis through retrograde transmission from the gut to the brain [26]. In the case of Polio, the enterovirus specifically targets motor neurons, resulting in cases that are clinically indistinguishable from ALS. Coxsackie and enterovirus 71 also target motor neurons and have been associated with outbreaks of acute flaccid paralysis in several regions of the globe, including in the US [27].

The establishment of a causal relationship between enteroviruses and motor neuron disease has resulted from epidemiological studies where the isolation of viral particles was discovered in spinal cord samples of affected patients with motor neuron disease [28]. In non-polio enteroviruses, amplification of a 414 base RNA target sequence in the conserved enterovirus 5' untranslated region was found in eight of 11 cases of sporadic motor neuron disease, suggesting that the class of enteroviruses display neurotrophic features similar to polio [29]. Subsequently, in later studies, qRT-PCR analysis of cerebrospinal fluid of EV-71, a newly emergent enterovirus detection was detected in 14.5% of 242 ALS patients and 7.6% of 354 controls [3].

It is believed that EV-71 emerged in the mid-20th century, as indicated by an analysis of viral capsid sequences similar to those found in other enterovirus genotypes belonging to common ancestral genogroups. The emergence of EV-71 was likely due to a recombination event between a portion of the genome of CV-A16 and the 5'-NTR of poliovirus. [30,31].

These shared nucleotide sequences between phenotypically different viral pathogens are likely based upon evolutionarily events between host and pathogen. Darwinian like pressures most likely have driven enteroviruses to "best fit strategies" in the context of population bottlenecks imposed by competitive forces in host- infection dynamics and mitochondrial energy barriers. As enteroviruses have high mutation rates, "best fit" sub-strains of enteroviruses categorically lead to the formation of quorums, where structural genes within the viral capsid maintain a degree of molecular fidelity across different viral species, which are noted as quasi-species [32].

In neurotrophic viruses including all enteroviruses, redundant RNA sequences within the viral capsid act as an "ancestral" hub for successful retroviral replication by encoding Activity-regulated cytoskeleton-associated protein (Arc-Gag complexes). The Arc-Gag complex facilitates the assemble of viral RNA genomes into a spherical virion [33]. Interestingly, evolutionary analysis indicates that Arc protein complexes are derived from retrotransposons, which are also ancestral to retroviruses with highly conserved homology to human protein isoforms, repurposed during evolution to mediate intra and intercellular communication at synaptic junctions via specific RNA sequences [34].

Part II: Raiders of the lost Arc: How viral Arc-Gag complexes produce neurodegeneration:

Neurotrophic viruses maintain a rudimentary level of "consciousness" with the capacity to "communicate" between separate species, "perceive" time and space at a molecular level and engage in "quorums" through neurotransmitter signaling through selective gene editing. These "best fit" strategies in the viral quorum are driven by phosphorylation- dephosphorylation pathways encoded within Arc to ensure viral particles to infect cells at the neuromuscular junction [35].

Within the viral capsid the Arc-Gag complex encodes several ATPase-dependent viral helicases which directly participates in enteroviral RNA replication [36]. It is interesting to note that activation of Arc results in epigenetic based histone modifications such as H3K27Ac which have recently been shown to be upregulated in late-onset Alzheimer's disease, suggesting its possible role in viral mediated neurodegeneration [37]. In support of this hypothesis, the Arc complex binds to the amyloid precursor protein and presenilin1 whereby genetic deletion of Arc reduces A β load in a transgenic mouse model of AD [38]. In humans, the Arc-Gag complex binds to calmodulin-dependent protein kinase II α and β (CaMKII α , and CaMKII β , respectively) resulting in cellular depolarization and the activation of glutamate and calcium channels (Zhang et al., 2019), well described pathways involved in the pathogenesis of neurodegeneration (Figure 1).




Figure 1. Virus-mediated excitotoxicity. The Arc-Gag complex normally interacts with the plasma membrane, weakening excitatory synapses. CaMKII α and β phosphorylates the Arc-Gag complex of the virions, decreasing its canonical function, leading to the clustering and activation of glutamate receptors and calcium efflux, which mediates excitotoxicity.

Viral capsid containing Arc-Gag complexes also induces protein aggregation due to excessive activation of CaMK-II [40] particularly the 3C protease to hijack the Endosomal Sorting Complex Required for Transport-III. Viral proteases are capable of penetrate nuclear pores surrounding the nucleus of host cells as a common feature of many structurally different viruses, including HIV[41]. Infection due to Coxsackievirus, for instance, has been shown to result in abnormal accumulation of insoluble, misfolded TDP-43 protein aggregates due to a 3C protease, which cleave TDP-43 rendering it incapable of acting as a critical anti-viral repressor protein [42,43]. In EV-71 infection, similar mechanisms relay to 3C proteases facilitates viral RNA replication [44]. Interestingly unbiased analysis of the Sars-Cov2 viral genome also has revealed capsid dependent release of protease 3C

protease, which has a direct effect on TDP-43 ectopic expression [45]. Thus, divergent viruses exert similar mechanisms of cytotoxicity involving the activation of 3C proteases suggesting an evolutionarily preserved feature of the Arc-Gag complex.

Gag polyproteins are the only viral protein required for the formation of viral budding as the nucleocapsid domain of Gag is responsible for recognition of specific dimerization and packaging signals in viral RNA [46]. Conversely, incomplete processing at any of the Gag cleavage sites is highly detrimental to virion by disrupting individual steps in the Gag processing cascade [47]. The Arc-Gag complex target host nucleoporins, (including nup62 which forms the central core of the nucleocapsid domain) to promote transport from the cytoplasm to the nucleus to ensure viral replication [48]. It is interesting to note that truncated forms of nup62 have been detected in pre-symptomatic stages of ALS [49].

Part III: The devil is in the details: The Arc-Gag complexes specifically modulates viral helicases.

The Arc-gag complex also encodes Na/K ATPase, a sodium/potassium mitochondrial enzyme where binding of the ATP1A1 domain results in the induction of viral endocytosis by alternative RNA splicing mechanisms [50]. Na/K-ATPase acts as a key scaffolding protein which interacts with protein kinase C and phosphoinositide 3-kinase, both of which have been implicated in ALS by regulating the phosphorylation status of adducin- a protein essential for the stability at the neuromuscular junction. Na/K ATPase changes the phosphorylation of adducin reducing the synaptic integrity at the neuromuscular junction in ALS [51]. Enrichment of α 2-Na/K ATPase (α 2-NKA) has been reported in astrocytes expressing mutant superoxide dismutase 1 [52]. Additionally, astrocytic α 2-NKA is elevated in postmortem human brain tissue from AD and progressive nuclear palsy, suggesting a common pathogenic link between overexpression of Na/K ATPase and neurodegeneration [53]. Furthermore, Na⁺/K⁺-ATPase also appears to modulate disease-specific conversion of prion proteins [54]. Whereas knockdown of α 2-Na/K ATPase in SOD1^{G93A} astrocytes markedly inhibited their ability to induce degeneration and protected motor neurons from degeneration in vivo [55].

Viral infectious also exert cytotoxicity through post translational mechanisms involving their ability to alter the phosphorylation status of RNA proteins, such as TDP-43, as mentioned earlier. These hyperphosphorylation events may occur as a result of infection-mediated changes in inorganic polyphosphates (PolyP). Polyp provides phosphate groups for ATP synthesis in all life forms, from viruses, bacteria and humans. As linear polymers, they are essential for the survival of enteropathogens, including E. Coli [56] and are used by bacterium to manufacture amyloid like biofilms [57] (Figure 2). In viral disease, PolyP provides phosphate groups for RNA polymerase enzymes to assist in the fidelity of the viral genome by providing phosphate groups to their nucleotide sequences. For example, in the case of poliovirus and enterovirus 71, genome maintenance and propagation are dependent on RNA-dependent RNA polymerases derived from polyphosphate [58].




Figure 2. PolyP in neurodegeneration. Viral infections lead to increased levels of PolyP, triggering the phosphorylation and aggregation of TDP-43, the formation of misfolded amyloid fibrils, and activation of P2Y1 receptors and, subsequently, calcium influx. TDP-43 buildup also contributes to the formation of toxic amyloid fibrils.

In the human brain, PolyP act as a gliotransmitter in astrocytes, whereby it stimulates the activation of intracellular calcium by binding to purinergic receptors P2Y₁ in the brainstem, resulting in calcium spikes and excessive depolarization of neurons [59]. Elevations of PolyP have also been shown to impair pathogen clearance, antagonize phagocyte recruitment, and suppresses hundreds of type I interferons-necessary for host immune viral repression [60]. Elevations of PolyP were first observed in 1955 in the CSF of over one hundred and four patients with polio [61]. More recently, increased polyphosphate concentrations were found in ALS astrocytes and in the CSF, resulting in

toxicity of motor neurons [62]. *In vitro*, PolyP binds to tau and accelerates its aggregation, in the presence of tubulin or microtubules [63]. Perhaps, this is the mechanism by which infusion of ALS-CSF in hTDP43^{WT} mice triggered motor and cognitive dysfunction, resulting in cytoplasmic TDP43 proteinopathy, neurofilament abnormalities and neuroinflammation [64]. Furthermore, TDP43 phosphorylation is mediated by defects in T cells immunity including specific subset receptors such as CD28 [65]. Defects in CD28 have been reported in ALS patients, suggesting a reduced capacity of naïve T cells to recognize common viral pathogens, resulting in immune senescent state [65]. Granulocyte-colony stimulating factor-CSF, an FDA-approved drug for cancer patients who are immune deficient, acts as a costimulatory factor for T cells CD receptors which when activated reduces TDP43 hyperphosphorylation [66].

Part IV: Unresolved questions

One of the most perplexing questions regarding the potential pathogenesis of ALS as a chronic infectious disease is why only certain individuals develop motor neuron disease and not others as these pathogens are ubiquitous in the population? According to the Koch hypothesis, only individuals who have evidence of a microbial infection should manifest a particular disease whereas those who do not have symptoms will not as otherwise the infection is not causal. Enteroviruses are common but only a small number of infected individuals develop signs and symptoms. Thus, viral infections are necessary, but not sufficient to trigger ALS. The likely explanation regarding only a subset of patients with enterovirus relates to the inherent capacity to develop ALS secondary to immunosenescent states imposed upon by viral mediated editing of adenosine to inosine, resulting in Adenosine deaminase deficiency and aberrant activation of antiviral innate immune. For example, in ALS neuronal astrocytic progenitor cells with C9orf72 or sporadic mutation have demonstrated defects in the conversion of adenosine to inosine secondary to adenosine deaminase deficiency [67].

In conclusion, viral induced neurodegeneration involves a pathological cascade beginning with the Arc-Gag protein complexes released by retrotransposons and retroviruses, which encodes specific viral helicases shared by HIV, and enteroviruses such as polio and others, such as EV-71. Release of these helicases results in abnormal RNA editing of RNA based proteins such as TDP-43 and adenosine deaminases which disrupt host defense mechanisms, resulting in viral derepression to enhance viral replication. The fact that viral enteropathogens recapitulate motor neuron disease through similar mechanisms that involves PolyP resulting in the formation of insoluble protein aggregates in an amyloid like manner, supports our hypothesis that ALS is virally-mediated.

Part V: Concluding remarks: A call to Arms:

The prospective validation of the viral hypothesis of ALS can be enabled by viral specific nucleic acids may be quantified using qPCR methods or by newer digital PCR methods. These emerging technologies can detect spliced versus un-spliced RNA in affected individuals at risk or displaying evidence of neurodegeneration. However, most current viral sequencing technologies provide no coverage of noncoding regions, for example in the untranslated region of polioviruses [68]. These new sequencing methods will ultimately fulfill the Koch hypothesis by proving causality, and in the event, offering the promise of targeted therapies for neurodegeneration. Prospective studies of the CSF of ALS patients involving elevations of inorganic polyphosphates should be considered to replicate previous findings by Arredondo, et al [62]. Various FDA-approved phosphatases, in this regard, act to reduce PolyP by promoting CD28-response elements by enhancing calcineurin, which in turn can target TDP43 as a disease modifying therapy. As ALS is an invariably fatal disease without a cure, the primary goal of this paper is to implore clinicians and researchers to look beyond our current theories of ALS pathogenesis and consider a broader explanation regarding the cause of ALS being infectious mediated.




Figure 3. The enteroviral hypothesis of neurodegeneration. Viral infections lead to TDP-43 phosphorylation and aggregation, altering RNA expression, activating pathological cascades, leading to cell dysfunction/death, and the characteristic symptoms of ALS.

Authors' contributions: J.L conceptualized and wrote the manuscript. A.D.K. wrote the article and made the figures. Both authors edited the text.

Funding: A.D.K. is funded by Fondecyt grant 1230317.

Ethical Approval: Not applicable.

Consent for publication: Not applicable.

Availability of data and materials: Not applicable.

Acknowledgement: The authors thanks Martha Beach Oleksandra Shchebet, for helpful discussions and all the wonderful researchers and clinicians at the Center for Neuroimmunology at Nova University in FL for their commitment to cure ALS.

Competing interests: The authors declare that there are no competing interests.

References

1. Arthur KC, Calvo A, Price TR, Geiger JT, Chiò A, Traynor BJ. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. *Nat Commun* [Internet]. Nature Publishing Group; 2016 [cited 2023 Apr 17];7. Available from: [/pmc/articles/PMC4987527/](https://pubmed.ncbi.nlm.nih.gov/26487527/)
2. Xue YC, Feuer R, Cashman N, Luo H. Enteroviral Infection: The Forgotten Link to Amyotrophic Lateral Sclerosis? *Front Mol Neurosci* [Internet]. Frontiers Media SA; 2018 [cited 2023 Apr 25];11. Available from: [/pmc/articles/PMC5857577/](https://pubmed.ncbi.nlm.nih.gov/315857577/)
3. Vandenberghe N, Leveque N, Corcia P, Brunaud-Danel V, Salort-Campana E, Besson G, et al. Cerebrospinal fluid detection of enterovirus genome in ALS: a study of 242 patients and 354 controls. *Amyotroph Lateral Scler* [Internet]. Amyotroph Lateral Scler; 2010 [cited 2023 Apr 17];11:277–82. Available from: <https://pubmed.ncbi.nlm.nih.gov/19900148/>
4. Fredericks DN, Relman DA. Sequence-based identification of microbial pathogens: a reconsideration of Koch's postulates. *Clin Microbiol Rev* [Internet]. Clin Microbiol Rev; 1996 [cited 2023 Apr 17];9:18–33. Available from: <https://pubmed.ncbi.nlm.nih.gov/8665474/>
5. Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. *Science* [Internet]. Science; 2008 [cited 2023 Apr 17];319:1668–72. Available from: <https://pubmed.ncbi.nlm.nih.gov/18309045/>
6. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Science* [Internet]. Science; 2006 [cited 2023 Apr 17];314:130–3. Available from: <https://pubmed.ncbi.nlm.nih.gov/17023659/>
7. Xiao S, Sanelli T, Dib S, Sheps D, Findlater J, Bilbao J, et al. RNA targets of TDP-43 identified by UV-CLIP are deregulated in ALS. *Mol Cell Neurosci* [Internet]. Mol Cell Neurosci; 2011 [cited 2023 Apr 17];47:167–80. Available from: <https://pubmed.ncbi.nlm.nih.gov/21421050/>
8. Tollervey JR, Curk T, Rogelj B, Briese M, Cereda M, Kayikci M, et al. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. *Nat Neurosci* [Internet]. Nat Neurosci; 2011 [cited 2023 Apr 17];14:452–8. Available from: <https://pubmed.ncbi.nlm.nih.gov/21358640/>
9. Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. *Nat Neurosci* [Internet]. Nat Neurosci; 2011 [cited 2023 Apr 17];14:459–68. Available from: <https://pubmed.ncbi.nlm.nih.gov/21358643/>
10. Liu EA, Mori E, Hamasaki F, Lieberman AP. TDP-43 proteinopathy occurs independently of autophagic substrate accumulation and underlies nuclear defects in Niemann-Pick C disease. *Neuropathol Appl Neurobiol* [Internet]. Neuropathol Appl Neurobiol; 2021 [cited 2023 Apr 25];47:1019–32. Available from: <https://pubmed.ncbi.nlm.nih.gov/34048071/>
11. Dardis A, Zampieri S, Canterini S, Newell KL, Stuani C, Murrell JR, et al. Altered localization and functionality of TAR DNA Binding Protein 43 (TDP-43) in niemann- pick disease type C. *Acta Neuropathol Commun* [Internet]. Acta Neuropathol Commun; 2016 [cited 2023 Apr 25];4. Available from: <https://pubmed.ncbi.nlm.nih.gov/27193329/>
12. Ou SH, Wu F, Harrich D, García-Martínez LF, Gaynor RB. Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. *J Virol* [Internet]. J Virol; 1995 [cited 2023 Apr 17];69:3584–96. Available from: <https://pubmed.ncbi.nlm.nih.gov/7745706/>
13. Cabrera-Rodríguez R, Pérez-Yanes S, Montelongo R, Lorenzo-Salazar JM, Estévez-Herrera J, García-Luis J, et al. Transactive Response DNA-Binding Protein (TARDBP/TDP-43) Regulates Cell Permissivity to HIV-1 Infection by Acting on HDAC6. *Int J Mol Sci. MDPI*; 2022;23.
14. Krug L, Chatterjee N, Borges-Monroy R, Hearn S, Liao WW, Morrill K, et al. Retrotransposon activation contributes to neurodegeneration in a Drosophila TDP-43 model of ALS. *PLoS Genet* [Internet]. PLoS Genet; 2017 [cited 2023 Apr 17];13. Available from: <https://pubmed.ncbi.nlm.nih.gov/28301478/>

15. Smethurst P, Sidle KCL, Hardy J. Review: Prion-like mechanisms of transactive response DNA binding protein of 43 kDa (TDP-43) in amyotrophic lateral sclerosis (ALS). *Neuropathol Appl Neurobiol* [Internet]. *Neuropathol Appl Neurobiol*; 2015 [cited 2023 Apr 17];41:578–97. Available from: <https://pubmed.ncbi.nlm.nih.gov/25487060/>
16. Chiang WC, Lee MH, Chen TC, Huang JR. Interactions between the Intrinsically Disordered Regions of hnRNP-A2 and TDP-43 Accelerate TDP-43's Conformational Transition. *Int J Mol Sci* [Internet]. Multidisciplinary Digital Publishing Institute (MDPI); 2020 [cited 2023 Apr 22];21:1–11. Available from: </pmc/articles/PMC7460674/>
17. Monette A, Mouland AJ. Zinc and Copper Ions Differentially Regulate Prion-Like Phase Separation Dynamics of Pan-Virus Nucleocapsid Biomolecular Condensates. *Viruses* [Internet]. Multidisciplinary Digital Publishing Institute (MDPI); 2020 [cited 2023 Apr 17];12. Available from: </pmc/articles/PMC7589941/>
18. Harrison AF, Shorter J. RNA-binding proteins with prion-like domains in health and disease. *Biochem J* [Internet]. *Biochem J*; 2017 [cited 2023 Apr 25];474:1417–38. Available from: <https://pubmed.ncbi.nlm.nih.gov/28389532/>
19. Gitler AD, Shorter J. RNA-binding proteins with prion-like domains in ALS and FTL-D. *Prion* [Internet]. *Prion*; 2011 [cited 2023 Apr 17];5:179–87. Available from: <https://pubmed.ncbi.nlm.nih.gov/21847013/>
20. Chen C, Ding X, Akram N, Xue S, Luo SZ. Fused in Sarcoma: Properties, Self-Assembly and Correlation with Neurodegenerative Diseases. *Molecules* 2019, Vol 24, Page 1622 [Internet]. Multidisciplinary Digital Publishing Institute; 2019 [cited 2023 Apr 17];24:1622. Available from: <https://www.mdpi.com/1420-3049/24/8/1622/htm>
21. Bellmann J, Monette A, Tripathy V, Sójka A, Abo-Rady M, Janosh A, et al. Viral Infections Exacerbate FUS-ALS Phenotypes in iPSC-Derived Spinal Neurons in a Virus Species-Specific Manner. *Front Cell Neurosci*. Frontiers Media S.A.; 2019;13:480.
22. Watts JC, Prusiner SB. β -Amyloid Prions and the Pathobiology of Alzheimer's Disease. *Cold Spring Harb Perspect Med* [Internet]. Cold Spring Harbor Laboratory Press; 2018 [cited 2023 Apr 25];8. Available from: </pmc/articles/PMC5554751/>
23. Bible JM, Pantelidis P, Chan PKS, Tong CYW. Genetic evolution of enterovirus 71: epidemiological and pathological implications. *Rev Med Virol* [Internet]. *Rev Med Virol*; 2007 [cited 2023 Apr 25];17:371–9. Available from: <https://pubmed.ncbi.nlm.nih.gov/17487831/>
24. Simmonds P, Gorbalenya AE, Harvala H, Hovi T, Knowles NJ, Lindberg AM, et al. Recommendations for the nomenclature of enteroviruses and rhinoviruses. *Arch Virol* [Internet]. *Arch Virol*; 2020 [cited 2023 Apr 17];165:793–7. Available from: <https://pubmed.ncbi.nlm.nih.gov/31980941/>
25. Kitamura N, Semler BL, Rothberg PG, Larsen GR, Adler CJ, Dorner AJ, et al. Primary structure, gene organization and polypeptide expression of poliovirus RNA. *Nature* [Internet]. *Nature*; 1981 [cited 2023 Apr 25];291:547–53. Available from: <https://pubmed.ncbi.nlm.nih.gov/6264310/>
26. Wells AI, Coyne CB. Enteroviruses: A Gut-Wrenching Game of Entry, Detection, and Evasion. *Viruses* [Internet]. Multidisciplinary Digital Publishing Institute (MDPI); 2019 [cited 2023 Apr 19];11. Available from: </pmc/articles/PMC6563291/>
27. Sejvar JJ, Lopez AS, Cortese MM, Leshem E, Pastula DM, Miller L, et al. Acute Flaccid Myelitis in the United States, August-December 2014: Results of Nationwide Surveillance. *Clin Infect Dis* [Internet]. *Clin Infect Dis*; 2016 [cited 2023 Apr 19];63:737–45. Available from: <https://pubmed.ncbi.nlm.nih.gov/27318332/>
28. Messacar K, Asturias EJ, Hixon AM, Van Leer-Buter C, Niesters HGM, Tyler KL, et al. Enterovirus D68 and acute flaccid myelitis—evaluating the evidence for causality. *Lancet Infect Dis*. Elsevier; 2018;18:e239–47.
29. Woodall CJ, Riding MH, Graham DI, Clements GB. Sequences specific for enterovirus detected in spinal cord from patients with motor neurone disease. *BMJ* : British Medical Journal [Internet]. BMJ Publishing Group; 1994 [cited 2023 Apr 19];308:1541. Available from: </pmc/articles/PMC2540520/?report=abstract>
30. Tee KK, Lam TT-Y, Chan YF, Bible JM, Kamarulzaman A, Tong CYW, et al. Evolutionary genetics of human enterovirus 71: origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene. *J Virol* [Internet]. *J Virol*; 2010 [cited 2023 Apr 19];84:3339–50. Available from: <https://pubmed.ncbi.nlm.nih.gov/20089660/>
31. McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance. *FEMS Microbiol Rev*. No longer published by Elsevier; 2002;26:91–107.

32. Domingo E. Molecular basis of genetic variation of viruses: error-prone replication. *Virus as Populations* [Internet]. Elsevier; 2020 [cited 2023 Apr 22];35. Available from: /pmc/articles/PMC7153327/
33. Bharat TAM, Noda T, Riches JD, Kraehling V, Kolesnikova L, Becker S, et al. Structural dissection of Ebola virus and its assembly determinants using cryo-electron tomography. *Proc Natl Acad Sci U S A* [Internet]. Proc Natl Acad Sci U S A; 2012 [cited 2023 Apr 17];109:4275–80. Available from: <https://pubmed.ncbi.nlm.nih.gov/22371572/>
34. Pastuzyn ED, Day CE, Kearns RB, Kyrke-Smith M, Taibi A V., McCormick J, et al. The Neuronal Gene Arc Encodes a Repurposed Retrotransposon Gag Protein that Mediates Intercellular RNA Transfer. *Cell*. Cell Press; 2018;172:275-288.e18.
35. Hantak MP, Einstein J, Kearns RB, Shepherd JD. Intercellular Communication in the Nervous System Goes Viral. *Trends Neurosci*. Elsevier Current Trends; 2021;44:248–59.
36. Xia H, Wang P, Wang GC, Yang J, Sun X, Wu W, et al. Human Enterovirus Nonstructural Protein 2CATPase Functions as Both an RNA Helicase and ATP-Independent RNA Chaperone. *PLoS Pathog* [Internet]. PLOS; 2015 [cited 2023 Apr 17];11. Available from: /pmc/articles/PMC4517893/
37. Leung HW, Foo G, VanDongen A. Arc Regulates Transcription of Genes for Plasticity, Excitability and Alzheimer’s Disease. *Biomedicines* [Internet]. Multidisciplinary Digital Publishing Institute (MDPI); 2022 [cited 2023 Apr 17];10. Available from: /pmc/articles/PMC9405677/
38. Wu J, Petralia RS, Kurushima H, Patel H, Jung MY, Volk L, et al. Arc/Arg3.1 Regulates an Endosomal Pathway Essential for Activity-Dependent β -Amyloid Generation. *Cell*. Cell Press; 2011;147:615–28.
39. Zhang W, Chuang YA, Na Y, Ye Z, Yang L, Lin R, et al. Arc Oligomerization Is Regulated by CaMKII Phosphorylation of the GAG Domain: An Essential Mechanism for Plasticity and Memory Formation. *Mol Cell*. Cell Press; 2019;75:13-25.e5.
40. Haolong C, Du N, Hongchao T, Yang Y, Wei Z, Hua Z, et al. Enterovirus 71 VP1 activates calmodulin-dependent protein kinase II and results in the rearrangement of vimentin in human astrocyte cells. *PLoS One* [Internet]. PLoS One; 2013 [cited 2023 Apr 17];8. Available from: <https://pubmed.ncbi.nlm.nih.gov/24073199/>
41. Kim Y, Lovell S, Tiew K-C, Mandadapu SR, Alliston KR, Battaile KP, et al. Broad-Spectrum Antivirals against 3C or 3C-Like Proteases of Picornaviruses, Noroviruses, and Coronaviruses. *J Virol* [Internet]. American Society for Microbiology (ASM); 2012 [cited 2023 Apr 22];86:11754. Available from: /pmc/articles/PMC3486288/
42. Rahic Z, Buratti E, Cappelli S. Reviewing the Potential Links between Viral Infections and TDP-43 Proteinopathies. *Int J Mol Sci* [Internet]. Multidisciplinary Digital Publishing Institute (MDPI); 2023 [cited 2023 Apr 17];24. Available from: /pmc/articles/PMC9867397/
43. Fung G, Shi J, Deng H, Hou J, Wang C, Hong A, et al. Cytoplasmic translocation, aggregation, and cleavage of TDP-43 by enteroviral proteases modulate viral pathogenesis. *Cell Death Differ* [Internet]. Nature Publishing Group; 2015 [cited 2023 Apr 17];22:2087. Available from: /pmc/articles/PMC4816113/
44. Pathinayake PS, Hsu ACY, Wark PAB. Innate Immunity and Immune Evasion by Enterovirus 71. *Viruses* [Internet]. Multidisciplinary Digital Publishing Institute (MDPI); 2015 [cited 2023 Apr 22];7:6613. Available from: /pmc/articles/PMC4690884/
45. Yang J, Li Y, Wang S, Li H, Zhang L, Zhang H, et al. The SARS-CoV-2 main protease induces neurotoxic TDP-43 cleavage and aggregates. *Signal Transduct Target Ther* [Internet]. Nature Publishing Group; 2023 [cited 2023 Apr 22];8. Available from: /pmc/articles/PMC9998009/
46. Gumna J, Purzycka KJ, Ahn HW, Garfinkel DJ, Pachulska-Wieczorek K. Retroviral-like determinants and functions required for dimerization of Ty1 retrotransposon RNA. *RNA Biol* [Internet]. Taylor & Francis; 2019 [cited 2023 Apr 19];16:1749. Available from: /pmc/articles/PMC6844567/
47. Waheed AA, Freed EO. HIV Type 1 Gag as a Target for Antiviral Therapy. *AIDS Res Hum Retroviruses* [Internet]. Mary Ann Liebert, Inc.; 2012 [cited 2023 Apr 19];28:54. Available from: /pmc/articles/PMC3251841/
48. Campbell S, Rein A. In Vitro Assembly Properties of Human Immunodeficiency Virus Type 1 Gag Protein Lacking the p6 Domain. *J Virol* [Internet]. American Society for Microbiology (ASM); 1999 [cited 2023 Apr 19];73:2270. Available from: /pmc/articles/PMC104472/
49. Ao Z, Jayappa KD, Wang B, Zheng Y, Wang X, Peng J, et al. Contribution of Host Nucleoporin 62 in HIV-1 Integrase Chromatin Association and Viral DNA Integration. *J Biol Chem* [Internet]. American Society

- for Biochemistry and Molecular Biology; 2012 [cited 2023 Apr 17];287:10544. Available from: /pmc/articles/PMC3322980/
50. Lingemann M, McCarty T, Liu X, Buchholz UJ, Surman S, Martin SE, et al. The alpha-1 subunit of the Na⁺,K⁺-ATPase (ATP1A1) is required for macropinocytic entry of respiratory syncytial virus (RSV) in human respiratory epithelial cells. PLoS Pathog [Internet]. PLOS; 2019 [cited 2023 Apr 17];15. Available from: /pmc/articles/PMC6695199/
 51. Krieger C, Wang SJH, Yoo SH, Harden N. Adducin at the Neuromuscular Junction in Amyotrophic Lateral Sclerosis: Hanging on for Dear Life. Front Cell Neurosci [Internet]. Frontiers Media SA; 2016 [cited 2023 Apr 22];10. Available from: /pmc/articles/PMC4731495/
 52. Gallardo G, Barowski J, Ravits J, Siddique T, Lingrel JB, Robertson J, et al. An α 2-Na/K ATPase/ α -adducin complex in astrocytes triggers non-cell autonomous neurodegeneration. Nature Neuroscience 2014 17:12 [Internet]. Nature Publishing Group; 2014 [cited 2023 Apr 17];17:1710–9. Available from: <https://www.nature.com/articles/nn.3853>
 53. Mann CN, Devi SS, Kersting CT, Bleem A V., Karch CM, Holtzman DM, et al. Astrocytic α 2-Na⁺/K⁺ ATPase inhibition suppresses astrocyte reactivity and reduces neurodegeneration in a tauopathy mouse model. Sci Transl Med [Internet]. American Association for the Advancement of Science; 2022 [cited 2023 Apr 19];14. Available from: <https://www.science.org/doi/10.1126/scitranslmed.abm4107>
 54. Graham JF, Kurian D, Agarwal S, Toovey L, Hunt L, Kirby L, et al. Na⁺/K⁺-ATPase Is Present in Scrapie-Associated Fibrils, Modulates PrP Misfolding In Vitro and Links PrP Function and Dysfunction. PLoS One [Internet]. PLOS; 2011 [cited 2023 Apr 17];6:26813. Available from: /pmc/articles/PMC3206849/
 55. Gallardo G, Barowski J, Ravits J, Siddique T, Lingrel JB, Robertson J, et al. An α 2-Na/K ATPase/ α -adducin complex in astrocytes triggers non-cell autonomous neurodegeneration. Nature Neuroscience 2014 17:12 [Internet]. Nature Publishing Group; 2014 [cited 2023 Apr 25];17:1710–9. Available from: <https://www.nature.com/articles/nn.3853>
 56. Li L, Rao NN, Kornberg A. Inorganic polyphosphate essential for lytic growth of phages P1 and fd. Proc Natl Acad Sci U S A [Internet]. National Academy of Sciences; 2007 [cited 2023 Apr 19];104:1794. Available from: /pmc/articles/PMC1794287/
 57. Lempart J, Jakob U. Role of Polyphosphate in Amyloidogenic Processes. Cold Spring Harb Perspect Biol [Internet]. Cold Spring Harbor Laboratory Press; 2019 [cited 2023 Apr 19];11. Available from: /pmc/articles/PMC6496346/
 58. Johnson RS, Strausbauch M, McCloud C. An NTP-driven mechanism for the nucleotide addition cycle of Escherichia coli RNA polymerase during transcription. PLoS One [Internet]. PLOS; 2022 [cited 2023 Apr 25];17. Available from: /pmc/articles/PMC9595533/
 59. Maiolino M, O'Neill N, Lariccia V, Amoroso S, Sylantsev S, Angelova PR, et al. Inorganic Polyphosphate Regulates AMPA and NMDA Receptors and Protects Against Glutamate Excitotoxicity via Activation of P2Y Receptors. The Journal of Neuroscience [Internet]. Society for Neuroscience; 2019 [cited 2023 Apr 21];39:6038. Available from: /pmc/articles/PMC6668208/
 60. Chrysanthopoulou A, Kambas K, Stakos D, Mitroulis I, Mitsios A, Vidali V, et al. Interferon lambda1/IL-29 and inorganic polyphosphate are novel regulators of neutrophil-driven thromboinflammation. J Pathol [Internet]. J Pathol; 2017 [cited 2023 Apr 25];243:111–22. Available from: <https://pubmed.ncbi.nlm.nih.gov/28678391/>
 61. Odessky L, Rosenblatt P, Sands IJ, Schiff I, Dubin FM, Spielsinger D, et al. Cerebrospinal fluid inorganic phosphorus in acute poliomyelitis; study of one hundred four patients. AMA Arch Neurol Psychiatry [Internet]. AMA Arch Neurol Psychiatry; 1955 [cited 2023 Apr 17];73:255–66. Available from: <https://pubmed.ncbi.nlm.nih.gov/14349427/>
 62. Arredondo C, Cefaliello C, Dyrda A, Jury N, Martinez P, Díaz I, et al. Excessive release of inorganic polyphosphate by ALS/FTD astrocytes causes non-cell-autonomous toxicity to motoneurons. Neuron [Internet]. Neuron; 2022 [cited 2023 Apr 17];110:1656-1670.e12. Available from: <https://pubmed.ncbi.nlm.nih.gov/35276083/>
 63. Wickramasinghe SP, Lempart J, Merens HE, Murphy J, Huettemann P, Jakob U, et al. Polyphosphate Initiates Tau Aggregation through Intra- and Intermolecular Scaffolding. Biophys J [Internet]. The Biophysical Society; 2019 [cited 2023 Apr 25];117:717. Available from: /pmc/articles/PMC6712485/

64. Mishra PS, Boutej H, Soucy G, Bareil C, Kumar S, Picher-Martel V, et al. Transmission of ALS pathogenesis by the cerebrospinal fluid. *Acta Neuropathol Commun* [Internet]. BioMed Central; 2020 [cited 2023 Apr 25];8. Available from: [/pmc/articles/PMC7206749/](#)
65. Britson KA, Ling JP, Braunstein KE, Montagne JM, Kastenschmidt JM, Wilson A, et al. Loss of TDP-43 function and rimmed vacuoles persist after T cell depletion in a xenograft model of sporadic inclusion body myositis. *Sci Transl Med* [Internet]. NIH Public Access; 2022 [cited 2023 Apr 28];14:eabi9196. Available from: [/pmc/articles/PMC9118725/](#)
66. Henriques A, Kastner S, Chatzikonstantinou E, Pitzer C, Plaas C, Kirsch F, et al. Gene expression changes in spinal motoneurons of the SOD1G93A transgenic model for ALS after treatment with G-CSF. *Front Cell Neurosci. Frontiers Media S.A.*; 2015;8:1–12.
67. Allen SP, Hall B, Castelli LM, Francis L, Woof R, Siskos AP, et al. Astrocyte adenosine deaminase loss increases motor neuron toxicity in amyotrophic lateral sclerosis. *Brain* [Internet]. Brain; 2019 [cited 2023 Apr 21];142:586–605. Available from: <https://pubmed.ncbi.nlm.nih.gov/30698736/>
68. Briesse T, Kapoor A, Mishra N, Jain K, Kumar A, Jadoo OJ, et al. Virome Capture Sequencing Enables Sensitive Viral Diagnosis and Comprehensive Virome Analysis. *mBio* [Internet]. American Society for Microbiology (ASM); 2015 [cited 2023 Apr 19];6. Available from: [/pmc/articles/PMC4611031/](#)

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.